Corgenix to Manufacture and Supply PLAC ELISA for diaDexus
19 Jun 2012
Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced yesterday that its wholly owned subsidiary, Corgenix, Inc., have entered into a contract manufacturing and supply agreement with diaDexus, Inc., a company focused on the development and commercialization of proprietary cardiovascular diagnostic products. Under the terms of the five-year agreement, Corgenix will manufacture and supply the PLAC® Test ELISA product for diaDexus.
The PLAC Test measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The American Association of Clinical Endocrinologists (AACE) recently announced the inclusion of Lp-PLA2 in its medical guidelines for clinical practice, an important endorsement of the clinical utility of Lp-PLA2 measurement. Specifically, the guidelines recommend the use of multiple markers, including Lp-PLA2, to assist physicians in personalizing therapy for elevations or other abnormalities in blood lipids. These abnormalities, commonly referred to as "dyslipidemia," are a major risk factor for coronary artery disease.
“We are pleased to announce this mutually beneficial relationship with diaDexus, which reflects Corgenix’s operational capacity to meet its long term growth expectations,” said Douglass Simpson, Corgenix President and Chief Executive Officer. “diaDexus is an outstanding company with extraordinary products which we expect will continue to grow significantly into the foreseeable future, and we look forward to supporting its growth initiatives.”
Corgenix management stated that the new agreement with diaDexus will be an important addition to the Company’s contract manufacturing program, contributing meaningful revenues in Fiscal 2013.
“We are confident that our renewed collaboration with Corgenix will provide us with the necessary manufacturing and support capabilities as we continue to see increased global acceptance of our PLAC Test,” said Brian Ward, diaDexus’ President and Chief Executive Officer. “We have worked with Corgenix successfully in the past and are confident that this relationship will be a positive step for both companies.”